AI for Biomarkers

Drug development and trial presuppose long and exhausting reviews of thousands, if not millions, of documents. For the success of any research, it is crucial to determine clinically important differences before and after treatment using biological markers. However, this process is extremely time-consuming and costly for any business.

More than that, the amount of data obtained in clinical trials is growing exponentially which makes this task even more complicated.

Altris AI is a unique solution for a pharma company that speeds up clinical research by automating biomarker detection on ophthalmic images and making it error-free.

AI for biomarkers is a digital solution to the problem of exhausting clinical research. Our system is trained on 5 mln OCT scans obtained from 11 practicing ophthalmic clinics, which guarantees high accuracy and zero human-made errors.

As of today, 70+ pathologies and biomarkers can be easily found with the help of the Altris AI system which can be customized for any client.

Using the biggest database of clinical cases, Altris AI can speed up any clinical research trial, making it much more effective and error-free.

Altris AI offers advanced AI for ophthalmic biomarkers, empowering pharmaceutical companies with precise, real-time analysis of OCT scans. Our platform detects and quantifies over 70 retinal pathologies and biomarkers, supporting biomarker-driven research, clinical trial recruitment, and therapeutic monitoring.

By automating the identification of biomarkers, Altris AI enables faster, more accurate insights across multi-site trials and observational studies. Compatible with all major OCT devices.

Our AI enhances data reliability and accelerates go-to-market timelines. Partner with Altris AI to unlock scalable, evidence-based solutions in ophthalmic drug development and post-market surveillance.

Pharma companies benefit from AI for retinal biomarkers by gaining faster, more accurate insights into disease progression and treatment response.

Accelerate patient enrollment, get clinical insights, and monitor the treatment results objectively.

This leads to enhanced patient stratification, better endpoint validation, and streamlined regulatory submissions. The platform also supports post-market surveillance with real-world data analysis, helping pharma teams track therapeutic efficacy over time. With Altris AI, pharma accelerates trial timelines, reduces costs, and improves confidence in ophthalmic product outcomes.